SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014884
Filing Date
2023-08-14
Accepted
2023-08-14 16:40:20
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20230630x10q.htm   iXBRL 10-Q 1007483
2 EX-31.1 anvs-20230630xex31d1.htm EX-31.1 13513
3 EX-31.2 anvs-20230630xex31d2.htm EX-31.2 13550
4 EX-32.1 anvs-20230630xex32d1.htm EX-32.1 5707
5 EX-32.2 anvs-20230630xex32d2.htm EX-32.2 5696
  Complete submission text file 0001558370-23-014884.txt   4939546

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20230630.xsd EX-101.SCH 30042
7 EX-101.CAL anvs-20230630_cal.xml EX-101.CAL 21845
8 EX-101.DEF anvs-20230630_def.xml EX-101.DEF 123356
9 EX-101.LAB anvs-20230630_lab.xml EX-101.LAB 250445
10 EX-101.PRE anvs-20230630_pre.xml EX-101.PRE 218820
52 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20230630x10q_htm.xml XML 953932
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 231171304
SIC: 2834 Pharmaceutical Preparations